Esperion to Participate in Upcoming 21st Annual Needham Virtual Healthcare Conference
29 mars 2022 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming Needham 21st...
Esperion to Participate in Upcoming Virtual Cowen 42nd Annual Healthcare Conference
24 févr. 2022 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Chief Medical Officer, Dr. JoAnne Foody, will participate in a Cardiometabolic/NASH focused panel, in...
Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
22 févr. 2022 07h00 HE
|
Esperion Therapeutics, Inc.
– Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022 – – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe)...
Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update
11 janv. 2022 08h00 HE
|
Esperion Therapeutics, Inc.
– Unprecedented CLEAR Outcomes Trial Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022; Achieved 85% MACE Accumulation in December – – Fourth-quarter 2021 U.S....
Esperion Appoints Benjamin O. Looker as General Counsel
04 janv. 2022 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced the appointment of Benjamin O. Looker as general counsel as of January 1, 2022. Mr. Looker will serve as...
Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021
12 nov. 2021 07h00 HE
|
Esperion Therapeutics, Inc.
- Analysis of pooled Phase 3 data showed that NEXLETOL [bempedoic acid (BA)] alone lowered LDL-C levels comparable to that of a moderate- or high-intensity statin (≥ 30%) in nearly 1 out of 3 of...
Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update
02 nov. 2021 07h00 HE
|
Esperion Therapeutics, Inc.
– Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth – – Unprecedented CLEAR Outcomes Study Remains...
Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021
01 nov. 2021 16h01 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021...
Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors
01 nov. 2021 07h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Seth H.Z. Fischer as a Class III director, with a term expiring at the 2022 meeting of...
ESPERION Announces Plan for Transformative Long-Term Growth
18 oct. 2021 07h00 HE
|
Esperion Therapeutics, Inc.
–Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial– –Reduces overall workforce by 40...